Confo Therapeutics, an emerging drug discovery company, has entered into a research collaboration and license agreement with Roche for the discovery, development, and commercialization of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders.
Under the terms of the agreement, Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercialization. The financial terms include an upfront payment, pre-clinical milestones and research funding to Confo Therapeutics totaling €6 million ($7.09 million) over the initial 30 months period of the collaboration.
In addition, Confo Therapeutics is eligible to receive up to €81.5 million ($96.37 million) of payments for certain development, regulatory, and commercial milestones, plus tiered royalties on the annual net sales of any products resulting from the collaboration.
Confo Therapeutics is a VUB-VIB spin-off co-founded in 2015 by VIB and Capricorn Venture Partners with the support of MINTS, PMV, QBIC, and V-Bio Ventures.
(Source: Confo Therapeutics)
Filed Under: Drug Discovery
